Welcome to our dedicated page for Replimune Group news (Ticker: REPL), a resource for investors and traders seeking the latest updates and insights on Replimune Group stock.
Replimune Group, Inc. (Nasdaq: REPL) generates frequent news as a clinical stage biotechnology company developing novel oncolytic immunotherapies based on its proprietary HSV‑1‑derived RPx platform. Headquartered in Woburn, Massachusetts and founded in 2015, the company focuses on product candidates such as RP1 (vusolimogene oderparepvec) and RP2, which are being studied across multiple difficult‑to‑treat cancers.
News related to Replimune commonly covers clinical trial updates from programs like IGNYTE, IGNYTE‑3, ARTACUS and REVEAL. These updates include data presentations at major medical meetings, such as the Society for Immunotherapy of Cancer (SITC) Annual Meeting and the European Society for Medical Oncology (ESMO) Congress, where the company has reported biomarker findings, response rates, durability of responses and safety data for RP1 plus nivolumab in advanced melanoma and non‑melanoma skin cancers.
Another major category of news involves regulatory milestones. Replimune has announced the FDA’s Complete Response Letter for the Biologics License Application (BLA) for RP1 in combination with nivolumab in advanced melanoma, subsequent Type A meetings with the FDA, and the agency’s acceptance of a BLA resubmission with a specified PDUFA target action date. These items are closely followed by investors and the oncology community because they reflect the evolving regulatory path for RP1.
Replimune’s news flow also includes corporate and financial updates, such as quarterly financial results, cash runway commentary, and equity‑based inducement grants to employees, as well as participation in investor conferences like the J.P. Morgan Healthcare Conference. Together, these announcements provide insight into the company’s operational progress, clinical development priorities and interactions with regulators.
Investors, clinicians and other stakeholders can use this news feed to track key developments around Replimune’s RPx platform, its lead programs in advanced melanoma and skin cancers, and the broader pipeline in metastatic uveal melanoma, hepatocellular carcinoma and biliary tract cancer.
Replimune Group, a clinical-stage biotechnology firm, has announced that its CEO, Philip Astley-Sparke, will present on January 10, 2022, at the 40th Annual J.P. Morgan Healthcare Conference. The event will be held virtually at 7:30 AM ET. A webcast will be accessible through Replimune’s website, with a replay available for 30 days. Founded in 2015, Replimune focuses on tumor-directed oncolytic immunotherapies, utilizing its proprietary RPx platform to enhance cancer treatment.
Replimune Group, Inc. (Nasdaq: REPL) has appointed Christy Oliger to its Board of Directors effective December 1, 2021. Oliger brings nearly 30 years of pharmaceutical and biotechnology experience, particularly in oncology, having previously held key roles at Genentech. CEO Philip Astley-Sparke expressed optimism about Oliger's contributions to the company’s leading pipeline of oncolytic immunotherapies. Replimune focuses on advancing its innovative immuno-gene therapy platform aimed at enhancing cancer treatment.
Replimune Group (Nasdaq: REPL) announced updated interim data from its Phase 1 trial of RP2, demonstrating strong responses in difficult-to-treat cancers. The trial includes both RP2 as a monotherapy and in combination with Opdivo. Notable findings include durable responses in patients with esophageal and mucoepidermoid carcinoma lasting 19-22 months. The 30-patient cohort with Opdivo showed a 23.3% partial response rate, with ongoing responses exceeding 425 days. The company plans to enroll an additional 24 patients with liver metastases in response to positive results.
Replimune Group (NASDAQ: REPL) reported a net loss of $29.4 million for Q2 2021, up from $20.1 million in Q2 2020. R&D expenses increased to $19.9 million, driven by expanded clinical programs. The company maintains a strong cash position of approximately $436 million, expected to fund operations into H2 2024. Full patient accrual in the CERPASS trial is anticipated by mid-2022, with primary data trigger expected by late 2022. Initial data from the IGNYTE trial is also set for late 2022, reinforcing Replimune's focus on establishing a robust skin cancer franchise.
Replimune Group, Inc. (NASDAQ: REPL) announced upcoming presentations at two key conferences. The first, BMO Biopharma Spotlight Series, occurs on November 8, 2021, focusing on next-gen oncolytic virus therapies. The second event, Piper Sandler 33rd Virtual Annual Healthcare Conference, runs from November 30 to December 2, 2021, featuring a pre-recorded fireside chat available on-demand starting November 22. Replimune develops innovative oncolytic immuno-gene therapies using its Immulytic® platform to enhance cancer treatment.
Replimune Group, Inc. (Nasdaq: REPL) announced four poster presentations at the Society for Immunotherapy of Cancer’s 36th Annual Meeting, scheduled for November 10-14, 2021. Key presentations include:
- RP2: Phase 1 trial with nivolumab for advanced solid tumors.
- ARTACUS: Phase 1b/2 study on RP1 in transplant recipients.
- CERPASS: Phase 2 study of cemiplimab ± RP1 for advanced squamous cell carcinoma.
- IGNYTE: Phase 1/2 trial of RP1 ± nivolumab in advanced tumors.
Full posters will be available on Replimune's website.
Replimune Group, Inc. (NASDAQ: REPL) announced updates on its ongoing clinical trials and financial results for Q1 2021. The company reported cash reserves of $458 million, sufficient to fund activities into H2 2024. Data for RP1 and RP2 indicate durable responses in advanced skin cancers, supporting ongoing trials, including the CERPASS study for cutaneous squamous cell carcinoma (CSCC). A Phase 2 program focusing on liver metastases is being designed, with plans to disclose details in early 2022. R&D expenses rose to $18.6 million, with a net loss of $27.3 million for the quarter.
Replimune Group (NASDAQ: REPL) announced that its management will present at two upcoming virtual conferences. The BTIG Virtual Biotechnology Conference is scheduled for August 9, 2021, at 11:00 am ET. The second event, the 2021 Wedbush PacGrow Healthcare Virtual Conference, will include a panel discussion on immuno-oncology challenges on August 11, 2021, at 12:35 pm ET. Replimune is focused on developing oncolytic immune-gene therapies to enhance cancer treatment effectiveness through its Immulytic® platform.
Replimune Group, Inc. (NASDAQ: REPL) announced that Dr. Robert Coffin, its President and Chief R&D Officer, will speak at the William Blair Biotech Focus Conference 2021. This virtual event is scheduled for July 14, 2021, at 4:20 PM ET, focusing on addressing PD-(L)1 refractory tumors. A webcast will be available on Replimune's website, with a replay accessible for 90 days. Replimune specializes in oncolytic immuno-gene therapies, leveraging its Immulytic® platform to enhance cancer treatment through improved immune responses and viral-mediated tumor cell killing.
Replimune Group announces encouraging interim results from its Phase 2 clinical trials involving RP1 combined with Opdivo for skin cancer treatments and RP2 for anti-PD1 failed cancers. The results highlight a high rate of complete responses, particularly in cutaneous squamous cell carcinoma, with a current complete response rate of 46%. Replimune plans to initiate a Phase 2 study targeting tumors with liver metastases, a critical unmet need. The virtual investor event is set for today at 8:00 am ET to discuss these findings and future plans.